Association between temporal changes in C-reactive protein levels and prognosis in patients with previous myocardial infarction - A report from the CHART-2 Study

被引:7
作者
Oikawa, Takuya [1 ]
Sakata, Yasuhiko [1 ,3 ]
Nochioka, Kotaro [1 ,3 ]
Miura, Masanobu [1 ,2 ,3 ]
Abe, Ruri [1 ]
Kasahara, Shintaro [1 ]
Sato, Masayuki [1 ]
Aoyanagi, Hajime [1 ]
Saga, Chiharu [1 ]
Ikeno, Yasuko [1 ]
Shiroto, Takashi [1 ]
Sugimura, Koichiro [1 ]
Takahashi, Jun [1 ]
Miyata, Satoshi [2 ]
Shimokawa, Hiroaki [1 ,2 ,3 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Evidence Based Cardiovasc Med, Sendai, Miyagi, Japan
[3] Tohoku Univ, Grad Sch Med, Big Data Med Ctr, Sendai, Miyagi, Japan
关键词
Myocardial infarction; C-reactive protein; Temporal change; CONGESTIVE-HEART-FAILURE; CARDIOVASCULAR-DISEASE; STATIN USE; INFLAMMATION; MARKERS; PREDICTION; MANAGEMENT; MORTALITY; OUTCOMES; RISK;
D O I
10.1016/j.ijcard.2019.07.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Several studies have reported that C-reactive protein (CRP), an inflammatory biomarker, predicts cardiovascular events independently of low-density lipoprotein cholesterol levels. However, no study examined whether temporal changes in CRP levels are associated with clinical events in patients with previous myocardial infarction (MI). Methods and results: We examined 2184 consecutive patients with previous MI and CRP data at baseline in the Chronic Heart Failure Registry and Analysis in the Tohoku district-2 (CHART-2) Study. During the median 6.4 years follow-up, 592 all-cause, 245 cardiovascular, and 273 non-cardiovascular deaths occurred. Patients with CRP >= 2.0 mg/L at baseline had significantly increased incidence of all-cause (hazard ratio (HR) 1.68, P < 0.001) and non-cardiovascular death (HR 1.86, P < 0.001), compared with those with CRP < 2.0 mg/L. Temporal changes in CRP levels were associated with prognosis; among patients with CRP >= 2.0 mg/L at baseline, those with CRP >= 2.0 mg/L at 1-year had significantly increased incidence of all-cause (HR 2.12, P < 0.001), cardiovascular (HR 2.31, P < 0.001), and non-cardiovascular death (HR 2.29, P < 0.001). Among patients with CRP < 2.0 mg/L at baseline, those with CRP >= 2.0 mg/L at 1-year had significantly increased incidence of all-cause (HR 1.76, P < 0.001) and cardiovascular death (HR 2.10, P = 0.001). These results remained significant after adjusted with the inverse probability of treatment weighted models using propensity sore. Furthermore, as compared with patients with CRP < 2.0 mg/L at both baseline and 1-year, those with CRP >= 2.0 mg/L at both baseline and 1-year had increased incidence of all-cause, cardiovascular, and non-cardiovascular death. Conclusions: These results provide the evidence that temporal increases in CRP levels are associated with increased clinical events in patients with previous MI. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1968, WHO TECH REP SER, V401, P1
[2]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[3]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[4]   Predictors of congestive heart failure in the elderly: The cardiovascular health study [J].
Gottdiener, JS ;
Arnold, AM ;
Aurigemma, GP ;
Polak, JF ;
Tracy, RP ;
Kitzman, DW ;
Gardin, JM ;
Rutledge, JE ;
Boineau, RC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (06) :1628-1637
[5]   C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis [J].
Kaptoge, Stephen ;
Di Angelantonio, Emanuele ;
Lowe, Gordon ;
Pepys, Mark B. ;
Thompson, Simon G. ;
Collins, Rory ;
Danesh, John ;
Tipping, R. W. ;
Ford, C. E. ;
Pressel, S. L. ;
Walldius, G. ;
Jungner, I. ;
Folsom, A. R. ;
Chambless, L. ;
Ballantyne, C. M. ;
Panagiotakos, D. ;
Pitsavos, C. ;
Chrysohoou, C. ;
Stefanadis, C. ;
Knuiman, M. W. ;
Goldbourt, U. ;
Benderly, M. ;
Tanne, D. ;
Whincup, P. ;
Wannamethee, S. G. ;
Morris, R. W. ;
Kiechl, S. ;
Willeit, J. ;
Mayr, A. ;
Schett, G. ;
Wald, N. ;
Ebrahim, S. ;
Lawlor, D. ;
Yarnell, J. ;
Gallacher, J. ;
Casiglia, E. ;
Tikhonoff, V. ;
Nietert, P. J. ;
Sutherland, S. E. ;
Bachman, D. L. ;
Keil, J. E. ;
Cushman, M. ;
Psaty, B. M. ;
Tracy, R. ;
Tybjaerg-Hansen, A. ;
Nordestgaard, B. G. ;
Zacho, J. ;
Frikke-Schmidt, R. ;
Giampaoli, S. ;
Palmieri, L. .
LANCET, 2010, 375 (9709) :132-140
[6]   Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. [J].
Lindahl, B ;
Toss, H ;
Siegbahn, A ;
Venge, P ;
Wallentin, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1139-1147
[7]   Cancer-related inflammation [J].
Mantovani, Alberto ;
Allavena, Paola ;
Sica, Antonio ;
Balkwill, Frances .
NATURE, 2008, 454 (7203) :436-444
[8]   NATURAL HISTORY OF CONGESTIVE HEART FAILURE - FRAMINGHAM STUDY [J].
MCKEE, PA ;
CASTELLI, WP ;
MCNAMARA, PM ;
KANNEL, WB .
NEW ENGLAND JOURNAL OF MEDICINE, 1971, 285 (26) :1441-1446
[9]   Statin Use and Reduced Cancer-Related Mortality [J].
Nielsen, Sune F. ;
Nordestgaard, Borge G. ;
Bojesen, Stig E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) :1792-1802
[10]   Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study [J].
Oikawa, Takuya ;
Sakata, Yasuhiko ;
Nochioka, Kotaro ;
Miura, Masanobu ;
Tsuji, Kanako ;
Onose, Takeo ;
Abe, Ruri ;
Kasahara, Shintaro ;
Sato, Masayuki ;
Shiroto, Takashi ;
Takahashi, Jun ;
Miyata, Satoshi ;
Shimokawa, Hiroaki .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (06)